Literature DB >> 3489736

Management of septic arthritis in children.

W A Herndon, S Knauer, J A Sullivan, R H Gross.   

Abstract

Forty-five children underwent initial nonoperative treatment of hematogenous septic arthritis in joints other than the hip. Only joints with symptoms for less than 6 days and without associated osteomyelitis were included. Thirty-four of the 49 joints were successfully managed by aspiration and antibiotics, whereas the remaining joints were successfully managed by surgical drainage following a lack of response to nonoperative treatment. All children had a satisfactory result after an average follow-up of greater than 3 years. Early diagnosis and treatment are more important than the method of drainage. If a lack of response is seen to initial nonoperative treatment, surgical drainage will still lead to a satisfactory outcome.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3489736     DOI: 10.1097/01241398-198609000-00009

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  4 in total

Review 1.  Septic arthritis in Western and sub-Saharan African children - a review.

Authors:  Christopher B D Lavy
Journal:  Int Orthop       Date:  2006-06-02       Impact factor: 3.075

2.  Treatment of Septic Arthritis of the Hip Joint Using Repeated Aspirations: When Should We Operate?

Authors:  Gilad Rotem; Noa Zur-Aviran; Nir Sherr-Lurie; Daniel Weltsch; Amos Schindler; Shay Tenenbaum; Uri Givon
Journal:  Indian J Orthop       Date:  2022-04-04       Impact factor: 1.033

3.  The limping child: an algorithm to outrule musculoskeletal sepsis.

Authors:  R A Delaney; B Lenehan; L O'sullivan; A J McGuinness; J T Street
Journal:  Ir J Med Sci       Date:  2007-07-12       Impact factor: 1.568

4.  Arthrocentesis, arthroscopy or arthrotomy for septic knee arthritis in children: a systematic review.

Authors:  Cornelia M Donders; Anne J Spaans; Johannes H J M Bessems; Christiaan J A van Bergen
Journal:  J Child Orthop       Date:  2021-02-01       Impact factor: 1.548

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.